What is Intra-Arterial (IA) Angioembolisation?
Intra-arterial angioembolisation (also called angiographic embolization or AG/AE) is a minimally invasive endovascular procedure where embolic materials (such as particles, coils, or microspheres) are delivered through a catheter directly into arteries feeding a target lesion to occlude blood flow and achieve hemostasis or tumor control.
Mechanism and Technique
The procedure involves:
- Arterial access via femoral or radial artery approach
- Selective catheterization of the target vessel using fluoroscopic guidance
- Delivery of embolic agents (PVA particles, coils, gelfoam, or drug-eluting beads) to occlude the bleeding vessel or tumor-feeding artery
- Immediate hemostasis through mechanical occlusion and thrombosis of the target vessel
The embolic materials are chosen based on the clinical indication—particles (300-500μm) for distal occlusion, coils (2-3mm) for proximal control, or specialized agents like drug-eluting beads for oncologic applications 1.
Primary Clinical Applications
Trauma Management (Hemorrhage Control)
In hemodynamically stable trauma patients with arterial blush on CT scan, AG/AE should be considered as a first-line intervention 2. The 2020 WSES guidelines provide clear algorithmic guidance:
- First-line use: Hemodynamically stable patients with contrast extravasation (arterial blush) on CT imaging should undergo AG/AE rather than immediate surgery (GoR 2B)
- Therapeutic indication: Documented active bleeding in liver, spleen, kidney, or adrenal injuries significantly reduces non-operative management failure rates 3
- Post-operative rescue: Persistent arterial bleeding after damage control surgery or non-hemostatic procedures warrants AG/AE (GoR 2A) 2
- Delayed hemorrhage: Bleeding without severe hemodynamic compromise should be managed first with AG/AE (GoR 2A) 2
- Pseudoaneurysm management: Hepatic artery pseudoaneurysms must be treated with AG/AE to prevent rupture (GoR 2A) 2
Critical caveat: In hemodynamically unstable non-responders, immediate operative management takes precedence over angioembolisation 2. However, in patients showing transient response to fluid resuscitation, AG/AE can be safe and effective even with hypotension 3.
Oncologic Applications
Transarterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (BCLC stage B) 4. The procedure combines:
- Intra-arterial delivery of chemotherapy (doxorubicin, epirubicin, cisplatin) emulsified with Lipiodol
- Followed by particle embolization to achieve vascular stagnation
- Results in both cytotoxic effect and tumor ischemia
TACE should NOT be used in patients with decompensated liver disease, advanced liver/kidney dysfunction, macroscopic vascular invasion, or extrahepatic spread (evidence high; recommendation strong) 4.
Alternative embolization techniques include:
- Transarterial bland embolization (TAE): Plain microspheres without chemotherapy
- Transarterial radioembolization (TARE): Yttrium-90 microspheres for targeted radiation delivery 5
Safety Profile and Outcomes
The procedure is minimally invasive with favorable safety outcomes:
- Recovery is practically painless compared to surgical alternatives 1
- Lower complication rates than open surgery
- Reduced hospitalization duration—often performed as outpatient procedure 5
- In trauma, 100% technical success rate reported even in hypotensive patients with transient fluid response 3
Common pitfalls to avoid:
- Do not perform preventive embolization indiscriminately—it's very effective in liver injuries with contrast blush but controversial in splenic trauma and provides no benefit in high-grade kidney injuries 3
- In hemodynamically stable children with liver trauma, contrast blush is NOT an absolute indication for AG/AE (GoR 2B) 2
- Requires immediate availability of trained interventional radiologists and appropriate imaging equipment 2
Clinical Decision Algorithm
For trauma patients:
- Hemodynamically unstable non-responders → Immediate operative management
- Hemodynamically stable with arterial blush on CT → AG/AE as first-line (GoR 2B)
- Transient responders to resuscitation → AG/AE can be attempted if immediately available
- Post-operative persistent bleeding → AG/AE as rescue therapy (GoR 2A)
- Delayed hemorrhage without severe compromise → AG/AE first-line (GoR 2A)
For oncologic indications:
- HCC BCLC stage B → TACE as standard of care
- Small renal masses → Thermal ablation preferred over embolization 5
- Contraindications present (decompensation, vascular invasion) → Avoid TACE
The procedure represents a paradigm shift from traditional surgical approaches, offering targeted therapy while preserving surrounding healthy tissue 5.